Inflammatory Skin Diseases Drug Development Pipeline Review, 2018: 17 Products in Development Featuring GlaxoSmithKline and Novartis

DUBLIN, June 11, 2018 /PRNewswire/ --

The "Inflammatory Skin Diseases Drug Development Pipeline Review, 2018" report has been added to ResearchAndMarkets.com's offering.

http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

There are 17 products in development for this indication, and companies operating in this space include GlaxoSmithKline and Novartis.

Molecular targets acted on by products in development for inflammatory skin disorders include cytokines, ribosomal RNA and retinoic acid receptors.

This report "Inflammatory Skin Diseases Drug Development Pipeline Review, 2018"provides an overview of the pipeline landscape for inflammatory skin disorders and comprehensive information on the therapeutics under development and key players involved in therapeutic development for acne vulgaris, rosacea and chronic urticaria (also known as hives). It also features dormant and discontinued products.

Scope

    --  Which companies are the most active within each pipeline?
    --  Which pharmaceutical approaches are the most prominent at each stage of
        the pipeline and within each indication?
    --  To what extent do universities and institutions play a role within this
        pipeline, compared to pharmaceutical companies?
    --  What are the most important R&D milestones and data publications to have
        happened in this disease area?

Reasons to buy

    --  Understand the overall pipeline, with an at-a-glance overview of all
        products in therapeutic development for each indication
    --  Assess the products in development in granular detail, with an
        up-to-date overview of each individual pipeline program in each
        indication and a comprehensive picture of recent updates and milestones
        for each
    --  Analyze the companies, institutions and universities currently operating
        in the pipeline and the products being fielded by each of these
    --  Understand the composition of the pipeline in terms of molecule type,
        molecular target, mechanism of action and route of administration.

Key Topics Covered:

1 Table of Contents

2 Introduction
2.1 Inflammatory Skin Diseases Report Coverage
2.2 Acne Vulgaris - Overview
2.3 Rosacea - Overview
2.4 Chronic Urticaria Or Hives - Overview

3 Therapeutics Development
3.1 Acne Vulgaris
3.2 Rosacea
3.3 Chronic Urticaria Or Hives

4 Therapeutics Assessment
4.1 Acne Vulgaris
4.2 Rosacea
4.3 Chronic Urticaria Or Hives

5 Companies Involved in Therapeutics Development
5.1 Acne Vulgaris
5.2 Rosacea
5.3 Chronic Urticaria Or Hives

6 Dormant Projects
6.1 Acne Vulgaris
6.2 Rosacea
6.3 Chronic Urticaria Or Hives

7 Discontinued Products
7.1 Acne Vulgaris
7.2 Rosacea
7.3 Chronic Urticaria Or Hives

8 Product Development Milestones
8.1 Acne Vulgaris
8.2 Rosacea
8.3 Chronic Urticaria Or Hives

9 Appendix

Companies Mentioned

    --  3SBio Inc
    --  Acne Vulgaris
    --  BioPharmX Inc
    --  Braintree Laboratories Inc
    --  Cassiopea SpA
    --  Cutanea Life Sciences Inc
    --  Daewoong Co Ltd
    --  Deltanoid Pharmaceuticals Inc
    --  ELORAC Inc
    --  Foamix Pharmaceuticals Ltd
    --  Galderma SA
    --  Helix BioMedix Inc
    --  Innovation Pharmaceuticals Inc
    --  Lee's Pharmaceutical Holdings Ltd
    --  LEO Pharma A/S
    --  Melinta Therapeutics Inc
    --  Novabiotics Ltd
    --  Novan Inc
    --  Novartis AG
    --  Paratek Pharmaceuticals Inc
    --  Pfizer Inc
    --  Phagelux Inc
    --  Phosphagenics Ltd
    --  Photocure ASA
    --  Promius Pharma LLC
    --  Provectus Biopharmaceuticals Inc
    --  Realm Therapeutics Plc
    --  Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
    --  Sol-GelTechnologiesLtd
    --  Sun Pharmaceutical Industries Ltd
    --  Valeant Pharmaceuticals International Inc
    --  Vyome Biosciences Pvt Ltd

For more information about this report visit https://www.researchandmarkets.com/research/kbq6ms/inflammatory_skin?w=5

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/inflammatory-skin-diseases-drug-development-pipeline-review-2018-17-products-in-development-featuring-glaxosmithkline-and-novartis-300663997.html

SOURCE Research and Markets